vaccine

Restaging raises hope against HPV oral cancer

Source: atlantajewishtimes.timesofisrael.com
Author: Cady Schulman

Jason Mendelsohn was diagnosed with Stage 4 tonsil cancer from HPV in 2014 after finding just one bump on his neck. He survived thanks to a variety of treatments, including a radical tonsillectomy and neck dissection to remove 42 lymph nodes, seven weeks of chemotherapy, radiation and a feeding tube.

But if Mendelsohn’s cancer had been discovered today, just four years later, it would have been classified as Stage 1. That’s because HPV-related oral cancers now have a high survival rate through a better response to treatment, said Meryl Kaufman, a speech pathologist specializing in head and neck cancer management who worked for Emory University’s department of head and neck surgery for 10 years.

“Cancer staging is taking into account the HPV-related cancers,” said Kaufman, who now owns her own practice. “It was kind of all lumped together. The survival rates for people who have HPV-related cancers are much higher than the typical head and neck cancers associated with smoking and drinking.”

For Mendelsohn, finding out that patients with HPV-related cancers likely face easier treatments and higher success rates made him extremely happy.

“If I was diagnosed and I heard Stage 1 instead of Stage 4, while it’s still cancer, it would make me feel like I could beat it,” said Mendelsohn, who made a video for his children a month after his diagnosis with advice for their lives after he was gone. “When I hear Stage 4 to Stage 1, I think people have hope they can beat it. My hope is that it will give people hope that they can beat this.”

As a cancer survivor, the Florida resident wants to give hope to other patients. He talks to people throughout the world every month and is creating a worldwide survivor patient network to connect cancer survivors with patients.

“While cancer is scary, Stage 1 is a lot less scary than Stage 4,” Mendelsohn said. “Stage 4 was overwhelming. When I was looking for information, there was nothing out there that made me feel like I was going to be OK. What I’m trying to do is give people hope and let them know that it’s all temporary.”

Another way Mendelsohn is trying to reach those affected by cancer is through his website, supermanhpv.com. He shares his story, news articles featuring him and oral cancer caused by HPV, and information for survivors, patients and caregivers.

The site also features Mendelsohn’s blog, putting himself out there so people can see that someone who, just four years ago, was diagnosed with Sage 4 cancer is now a Peloton-riding, travel-loving cancer advocate.

“People see me and say (they) can’t believe (I) had cancer three to four years ago,” Mendelsohn said. “I was in bed 18 hours a day for a month. I was choking on my saliva for a month. I was consuming five Ensures a day and two Gatorades a day through a feeding tube in my stomach. If people going through that can see me working out, going on the bourbon tour in Louisville. I’ve been on an Alaskan cruise. I’ve been to the Caribbean. I’ve been to the Grand Canyon.”

Mendelsohn, who started his campaign to raise awareness of HPV and oral cancer by raising money for the Ride to Conquer Cancer in Washington, now serves on the board of the Head and Neck Cancer Alliance. The organization’s goal is to advance prevention, detection, treatment and rehabilitation of oral, head and neck cancers through public awareness, research, advocacy and survivorship.

“I feel like it’s gone from me raising money for a bike ride to me on two boards helping create awareness and raise inspiration and creating a survivor patient network,” Mendelsohn said. “Now it’s not about me and my three doctors. Now it’s about helping people with diagnosis globally. There are great doctors. I think we’re going to do great things.”

One way to help prevent children from getting cancer caused by HPV when they grow up is the Gardasil vaccine, which protects against HPV Strain 16, which causes oral cancer. Mendelsohn said 62 percent of college freshmen and three-quarters of adults by age 30 have HPV.

But he doesn’t tell people to get the vaccine. Instead, he advises parents to talk to their kids’ doctors about the benefits and risks.

“I talk about the importance of oral cancer screenings when they’re at the dentist,” he said. “And if you feel a bump on your neck, go to your ENT. I had no symptoms and just a bump on my neck, but I was diagnosed with Stage 4. I’ve had so many tell me that they didn’t know the vaccine is for boys. They thought it was just for girls.”

Kaufman said that the HPV vaccine is recommended for use in boys and girls and that it’s important for the vaccine to be given before someone becomes sexually active. The vaccine won’t work if a person has already been exposed to HPV, as most sexually active adults have been, she said.

Men are much more likely to get head and neck cancer from HPV.

“Usually your body fights off the virus itself, but in some people it turns into cancer,” Kaufman said. There hasn’t been specific research that the HPV vaccine will protect you from head and neck cancer, she said, “but if you’re protected against the strains of HPV that cause the cancer, you’re probably less likely to get head and neck cancer.”

Treatment for this cancer isn’t easy, Kaufman said. Radiation to the head and neck can affect salivary glands, which can cause long-term dental and swallowing issues. Treatment can affect the skin, taste and the ability to swallow.

“A lot of people have tubes placed,” she said. “It’s not easy. It depends on how well you respond to the treatment.”

While getting the vaccine can help protect against various cancers, awareness about head and neck cancer is the key. And knowing the signs and symptoms — such as sores in the mouth, a change in voice, pain with swallowing and a lump in the neck — is important.

“If one of those things lasts longer than two weeks, you should go to your doctor,” Kaufman said. “This can affect nonsmokers and nondrinkers. It’s not something that people expect. The more commonplace it becomes and the less stigma, the better.”

Doctors paying for sons to have cancer jab

Source: www.bbc.com
Author: Anna Collinson, Reporter, Victoria Derbyshire programme

Doctors and health professionals are regularly paying hundreds of pounds for their teenage sons to receive a vaccination against cancer that girls already receive for free on the NHS, the Victoria Derbyshire programme has been told. Is boys’ health being put at risk?

“Had the HPV vaccine been available when I was a boy, I believe I would not have developed throat cancer more than 30 years later,” said Jamie Rae, 53.

“I’m basing this on the overwhelming majority of research I have seen over the years and countless experts I have spoken to.

“That’s why I’m desperate for boys to be able to receive it.”

HPV is the name given to a large group of viruses. It is very common and can be caught through any kind of sexual contact with another person who already has it. Doctors say 90% of HPV infections go away by themselves – but sometimes infections can lead to a variety of serious problems. For boys, this includes cancer of the anus, penis, mouth and throat.

Since 2008, girls aged 12 to 18 across the UK have been offered HPV vaccinations as part of the NHS childhood vaccination programme. It is currently not offered to boys of the same age, but it can be done privately, costing several hundred pounds.

Mr Rae founded the Throat Cancer Foundation after the treatment he received in 2010. He said at the time there was little information on HPV and he did not want anyone to go through his experience.

“I had radiotherapy for 35 days except weekends. I felt extreme burning in my neck and mouth and I was covered in sores. The pain was excruciating,” he explained. “It’s a lengthy recovery time. You have to teach yourself to swallow again and you get a dry mouth all the time.”

His foundation is part of HPV Action – which represents more than 50 groups and charities that are calling for both genders to receive the vaccination on the NHS.

‘Indefensible’
Mr Rae said the current disparity between boys and girls was “appalling”.

“Lots of doctors are having their boys vaccinated because they can afford it, as are those who are better informed,” he said. “But what about those who can’t afford it? Cases of throat cancer are soaring. It’s indefensible.

“Every day that goes past where boys are not being vaccinated condemns them to a whole host of diseases that we could prevent.”

HPV Action says around a dozen countries including Australia, Canada and the US are already vaccinating boys or are planning to do so in the near future. The government’s vaccination advisory committee is currently reviewing whether boys should receive the HPV vaccination.

A spokesperson for the Department of Health and Social Cares says it will carefully consider its advice once they’ve received it. Campaigners hope there will be a decision this year, possibly as soon as June. A debate is taking place on Wednesday at Westminster Hall about the issue.

The argument for vaccinating boys against HPV:

  • About 15% of UK girls eligible for vaccination are currently not receiving both doses, a figure which is much higher in some areas
  • Most older women in the UK have not had the HPV vaccination
  • Men may have sex with women from other countries with no vaccination programme
  • Men who have sex with men are not protected by the girls’ programme
  • The cost of treating HPV-related diseases is high – treating anogenital warts alone in the UK is estimated to cost £58m a year, while the additional cost of vaccinating boys has been estimated at about £20m a year

Source: HPV Action

What’s the link between HPV and head and neck cancer?

Source: blogs.bcm.edu
Author: Dr. Michael Scheurer

As a molecular epidemiologist, I’ve been conducting research on human papillomavirus (HPV)-related cancers since my dissertation work in 2003. While working with the clinical faculty here at Baylor College of Medicine, I’ve heard many questions lately about the possibility of the HPV vaccine “helping treat” head and neck cancer (HNC).

It’s important to know the link between HPV and HNC because patients with HPV-positive tumors often have better survival rates than those with HPV-negative tumors. Check out these frequently asked questions to learn more about HPV and HNC.

What is HPV?

  • HPV is a sexually transmitted infection that can infect the oral cavity, tonsils, back of throat, anus, and genitals.
  • There are many types of HPV. Some types can cause cancer and other types can cause warts.
  • HPV infection is very common in the U.S. with more than 50 percent of adults being infected at some point in their lifetime.
  • There is no treatment for HPV infection.
  • For some people, their HPV infection naturally clears while others develop cancer after many years.

What is oropharyngeal cancer?

  • Oropharyngeal cancer occurs in the tonsils and back of throat.
  • In the U.S., HPV now causes most oropharyngeal cancers.
  • Most doctors would recommend that oropharyngeal cancers be tested for HPV.
  • Smoking and alcohol use can also increase risk of developing oropharyngeal cancer.

How did I get HPV infection in my mouth or throat?

  • The most likely route of exposure is by oral sex, although other routes may exist.
  • Performing oral sex and having many oral sex partners can increase your chances of oral HPV infection.
  • HPV is not transmitted casually by kissing on the cheek or sharing a drink with someone.
  • We do not know for sure if HPV is transmitted by open-mouth or “French” kissing.

What does it mean as a HNC patient if I have HPV in my tumor?

  • Many studies have shown that oropharyngeal cancer patients with HPV in their tumor have a better outcome than people without HPV.
  • These patients tend to respond better to both chemotherapy and radiation treatment for HNC. Appropriately selected patients also have excellent outcomes after surgery.

Is the HPV vaccine for me?

  • The HPV vaccines work by preventing people from getting new HPV infections.
  • These vaccines do not treat HPV infection or the cancers that HPV cause.
  • The vaccines are currently recommended for people ages nine to 26 years old.
April, 2018|Oral Cancer News|

HPV is causing an oral cancer epidemic in men by outwitting natural defenses

Source: www.philly.com
Author: Marie McCullough, staff writer

Five years ago, when actor Michael Douglas candidly revealed that his throat cancer was linked to having oral sex, two things happened.

He made headlines that mortified his family. And he helped publicize the fact that a pervasive, sexually transmitted virus called HPV was unleashing an epidemic of oral cancer among men.

Since then, scientists have made headway in figuring out why HPV, the human papillomavirus, has this glaring gender bias. Men are four times more likely than women to be diagnosed with oral cancer, a hard-to-detect, hard-to-treat disease that has overtaken cervical cancer as the most common HPV-related malignancy in the United States.

To be sure, changes in sexual norms over the last few generations have played a role in this alarming trend. But research increasingly shows the real problem is something men have practically no control over: their immune response.

Compared with women, men are more likely to get infected with HPV — including “high-risk” cancer-causing strains. They also are less able to wipe out infection on their own, and more likely to get reinfected. The reasons are unclear.

“There is good evidence that men acquire oral infections more readily than women, even if they have similar sex practices,” said Ashish A. Deshmukh, a University of Florida HPV researcher. “And more than the acquisition, it’s the persistence of the virus. The clearance rate is not that fast in men.”

Michael Becker of Yardley has stepped up as the face of this immunological inequity. The 49-year-old former biotech executive is health-conscious, clean-living, happily married for 26 years – and battling terminal oropharyngeal cancer, the medical term for malignancies in parts of the mouth and throat.

He’s also battling the misconceptions and ignorance that keep too many parents from protecting their pubescent children — especially boys — against HPV-driven cancers. Two shots. That’s all it takes for the leading vaccine, Gardasil, to prevent most cervical cancers, less common genital malignancies, and the disease that is killing Becker.

“I can’t tell you how many emails I got from parents after the CBS segment,” he said, referring to a national television interview last month. “They said, ‘What do you mean this vaccine is for boys?’ and ‘What do you mean oral cancer incidence has eclipsed cervical cancer?’ ”

An inescapable virus
HPV is a family of more than 100 virus types that can live in the flat, thin cells on the surface of the skin, cervix, vagina, anus, vulva, penis, mouth, and throat. The virus is spread through contact with infected skin, mucous membranes, and bodily fluids. Some types can be passed during intercourse or — as Douglas pointed out — oral sex. While virtually all sexually active people will get infected at some point, the virus is usually wiped out by the immune system without so much as a symptom.

But not always.

In the cervix, persistent infection with high-risk HPV types can lead to precancerous changes that, left alone, slowly turn malignant. Fortunately, the Pap smear enables the detection and removal of abnormal cells before cancer develops. What’s more, age-related changes in cervical cells reduce the risk that HPV will take hold there as women get older.

No such screening test exists for oropharyngeal sites – the tongue, soft palate, tonsils, the throat behind the nasal cavity – and symptoms usually don’t appear until cancer is advanced. Becker, for example, had metastatic disease by the time he noticed a lump under his jaw line in late 2015.

Traditionally, smoking and heavy alcohol use are the big risk factors for oral cancer, but the non-HPV tumors linked to these bad habits have been declining in recent years. HPV-related tumors, in contrast, have increased more than 300 percent over the last 20 years. The virus is now found in 70 percent of all new oral cancers.

About 13,200 new HPV oral cancers are diagnosed in U.S. men each year, compared with 3,200 in women, according to federal data. Treatment — surgery, chemotherapy, radiation — can have disfiguring, disabling side effects. About half of late-stage patients die within five years.

Natural defenses go awry
Oral HPV infection rates are skewed by gender, just like the resulting cancers. The latest national estimates of this disparity, published in October, come from Deshmukh and his University of Florida colleagues. They used a federal health survey that collected DNA specimens to estimate that 7.3 percent of men and 1.4 percent of women have oral infections with high-risk HPV types. That translates to 7 million men and 1.4 million women.

The chance of oral infection increases for women as well as men who have simultaneous genital HPV infections or a history of many sex partners, but male infection rates still far surpass female rates.

Patti Gravitt, an HPV researcher at George Washington University, believes these estimates are a bit oversimplified because women counted as uninfected may actually have undetectably low virus levels, or HPV may be hiding in a dormant state in their cells.

Still, Gravitt said the study is in line with others that suggest “men are more susceptible to HPV viral infection than women.”

In women, an HPV infection usually sets off the body’s defense mechanisms. The immune system makes antibodies that kill off the invader, then immune cells remain on guard, ready to attack if the virus reappears.

But in men, something goes awry. The HIM study — for HPV in Men — documented this by collecting genital, anal, and oral samples from 4,100 unvaccinated men in Florida, Mexico and Brazil between 2005 and 2009. The samples were tested for the presence of two high-risk HPV types and two that cause genital warts.

Among 384 men who developed infections during a 24-month period, only 8 percent produced antibodies. But this response rate varied depending on the site of infection; none of the small number of orally infected men produced antibodies.

Rather than putting the immune system on guard and protecting men from the virus, infection sharply increased the chance of getting infected again with the exact same HPV type. And many men who got reinfected were celibate at the time.

How could this be? Anna R. Giuliano, the researcher at the Moffitt Cancer Center in Tampa, Fla., who led the HIM study, said recurring infections may be due to reactivation of dormant virus, or to auto-inoculation – the man spreads infection from one part of his body to another. Or to something else entirely.

While the scientific understanding of this puzzle is evolving, one implication is clear. “HPV vaccination is the only reliable method to ensure immune protection against new HPV infections and subsequent disease in males,” Giuliano and her co-authors declared in a recent paper.

Becker hammers that message – when he is not being hammered by chemotherapy – using his self-published memoir and his blog. This week’s blog gave a shout-out to Sunday’s first-ever International HPV Awareness Day, declared by Giuliano and other members of the International Papillomavirus Society.

Becker realizes that the novelty of the vaccine, the complexity of HPV, and its link to sex are obstacles to immunization. But he focuses on the life-saving aspect.

“Parents are being asked to vaccinate their 11-year-old child and they can’t imagine 30 or 40 years down the line, it will prevent cancer,” Becker said. “If you don’t know it’s connected to six cancers, you’re not going to care. So it really should be cast as an anti-cancer vaccine.”

March, 2018|Oral Cancer News|

HHC study supports web-based care plans for head, neck cancer patients

Source: www.hartfordbusiness.com
Author: John Stearns

A joint study by the Hartford HealthCare (HHC) Cancer Institute and the Memorial Sloan Kettering (MSK) Cancer Center has demonstrated benefits of a web-based care plan for patients with head and neck cancer as a tool to better cope with side effects of treatment.

A web-based tool to help patients with head and neck cancer better deal with effects of their cancer treatment has proved beneficial to patients and doctors, according to a HHC doctor involved in developing the tool and studying its effectiveness.

“The compelling reason to do this work is because head and neck cancer has changed,” said Dr. Andrew Salner, medical director of the Hartford HealthCare Cancer Institute at Hartford Hospital, HHC’s lead doctor on the joint study with MSK.

Head and neck cancer, once mostly associated with heavy drinkers and smokers who had other chronic diseases, is showing up more in younger and healthier patients, he said. That’s because of the prevalence of human papillomavirus (HPV), now the leading cause of the cancers that often target the tonsils and back of the tongue.

HPV is the most commonly sexually transmitted infection in the U.S. HPV is equally divided among males and females, the latter who’ve been getting vaccinated against HPV to prevent cervical cancer, but oral cancers are happening more prevalently and are appearing in males and females, Salner said. As such, boys and girls are now recommended for the vaccine before they become sexually active to hopefully prevent future disease, he said.

Immunization rates were 38 percent for boys and 50 percent for girls in 2016, Salner said.

Most people with HPV will not develop cancer, according to HHC, but for those who do, treatment outcomes are good, but the effects of head and neck cancer treatment can cause difficulty with taste and swallowing, dental problems, jawbone injury, underactive thyroid and other issues, Salner said.

The study of 43 head and neck cancer patients in Hartford and New York tracked the benefit of a web-based care plan tailored to their specific cancer, treatment and side effects. Historically, so-called survivorship care plans were fairly generic in addressing issues patients might or might not encounter, Salner said.

“This study was unique because it personalized the side effects for the tumor site and the treatment for each patient,” Salner said. It offers specific effects to watch for, some of which may not show up for years after treatment, ways to help prevent problems, cope with treatment side effects and timelines for follow-up medical screenings.

“The patients really appreciated all components of the care plan,” which also included a 60- to 90-minute meeting to review with medical staff.

HHC and MSK are talking with the National Cancer Institute to do a much wider study of the care plan, Salner said. He also wants to examine how to scale up the plan for larger populations and integrate it into patients’ medical records.

Salner and Dr. David Pfister, chief of head and neck oncology services at the MSK Cancer Center, will discuss the study and link between HPV and head and neck cancer in a talk this afternoon, from 4 to 5, at the Hartford Hospital Wellness Center at Blue Back Square, West Hartford.

February, 2018|Oral Cancer News|

HPV leads to increase In head and neck cancer In men

Source: www.nbcdfw.com
Author: Bianca Castro

The number of men diagnosed with head and neck cancer caused by human papillomavirus has skyrocketed. This report found that 11 million men and 3.2 million women in the United States are infected with some type of oral HPV and oncologists say it’s leading to more head and neck cancer in men.

“From the 1970’s to today, the prevalence of this HPV-related head and neck cancer has increased by three to five percent per year from then until now, and it is continuing that same rate,” said Oncologist Jerry Barker, Jr., M.D. at Texas Oncology.

“This is a silent epidemic. Most patients who are exposed to this virus, they don’t know it. They’ll never have symptoms from it, but some of those patients will move on to develop a cancer,” said Dr. Barker.

Jeff Busby, of Weatherford, is one of those patients. The aerospace engineer and owner of Busby Quarter Horses says he was diagnosed with throat cancer in February of 2016. His wife Andrea, who documented their journey here, says they were both shocked.

“We were just busy living life. You don’t ever think that shoe is going to drop,” said Andrea.

Jeff says the symptoms began as pain in his ear which lead to pain in his throat. Nine months later, he had a biopsy done on what was a mass in his neck.

“I had just been toughing it out and my partner said, ‘hey, you can’t just tough these kinds of things out. You’ve got to go get this checked out,'” said Jeff.

“It was the cancer putting pressure on and radiating nerve pain to the ear. There was nothing wrong with the ear whatsoever,” said Jeff.

A biopsy revealed Jeff had throat cancer caused by the human papillomavirus, the most common sexually transmitted infection.

Jeff was likely exposed in his teens or 20s, but now decades later, created a cancer with one of the most gruesome treatment protocols. He needed surgery to remove his bottom teeth and part of his jaw, 35 radiation treatments and six rounds of chemotherapy.

“I couldn’t let any of my energy go towards feeling sorry for myself because I had to have every amount of energy I had to beat this thing,” said Jeff.

Jeff had never heard of HPV before, while Andrea says she thought it was linked to only cervical cancer.

While pap smears screen for cervical cancer, there is no screening for hpv-related head and neck cancer and that may be part of the reason rates of hpv-related head and neck cancer has surpassed the rate of hpv-related cervical cancer.

There is way to stop the epidemic. The HPV vaccine is recommended for children as early as 11-years-old and young adults as old as 26 years of age. However, according to this study, in Texas, only 35 percent of children get the vaccine.

“Somewhere along the way, these vaccines developed the idea that they had to do with human sexuality and preventing a sexually transmitted disease, but in reality, they are designed to prevent cancer. These are cancer vaccines,” said Dr. Barker.

“If you could just see what some of our patients have to go through to cure one of these cancers, you would run to get the needle in the arm to prevent that from happening to one of your children.”

At 55, Jeff never had the chance to benefit from the vaccine, approved for use in 2006. He’s now cancer free and in some ways, he says, life is better than before cancer.

“I thank God for this challenge and I still wouldn’t change it today. I wouldn’t take it all away because I didn’t think I could be closer to the Lord or to my wife and I certainly have a much better relationship with both,” said Jeff.

He and Andrea are focused on raising vaccination rates and preventing the kind of cancer battle they fought from from happening to someone else.

“There are so many parents that even hear about but still choose not to do it. It’s beyond me. I can’t understand that,” said Jeff.

“Whether it gets a kid vaccinated or somebody sitting on their couch goes, ‘I have ear pain when I swallow. I should go to the doctor.’ That’s why we are doing this,” said Andrea.

The Centers for Disease Control estimates that most Americans have some type of HPV strain but not all strains lead to cancer. Some of the symptoms are head and neck cancer include ear pain, difficulty swallowing and a painless lump on the side of the neck.

January, 2018|Oral Cancer News|

HPV vaccine IS safe and effective, confirms longest-ever study into the shot which prevents cancer of the cervix, head, neck throat and penis

Source: www.dailymail.co.uk
Author: Mia De Graaf, Health Editor

The HPV vaccine is safe and effective at preventing human papilloma virus, according to the longest investigation ever conducted on the relatively new shot. While the vaccine has been a success in every study since it came out in the US and the UK in 2006, the medical community has been keenly waiting for some long-term data to show its lingering benefits.

Today, Augusta University’s 10-year study was published in the journal Pediatrics, appearing to confirm the findings in every other short-term report. The data also supported the view that the vaccine should be administered to both boys and girls from the age of nine years old, despite previously only being offered to girls.

Experts say they hope the findings will help drive up rates of children getting the vaccine, which protects against HPV and therefore HPV-linked cancers such as throat, head, neck, penis, and cervical cancer.

‘The vaccine was virtually 100 percent effective in preventing disease in these young individuals,’ says Dr Daron G. Ferris, professor in the Department of Obstetrics and Gynecology at the Medical College of Georgia and at the Georgia Cancer Center at Augusta University.

HPV is the most common sexually transmitted infection in the US and the UK with an estimated 14 million Americans infected every year, and a third of British adults. While about two-thirds of infected individuals can eventually clear the virus, it persists and can cause a wide range of health problems in the remainder, including a whole host of cancers.

The researchers tracked 1,661 people in 34 sites across nine countries, assessing the effectiveness of the three-shot vaccine – which is the format offered in the US, while UK citizens get a two-shot vaccine.

At first, a third of the participants received a placebo. But within 30 months, they also received the vaccine. They started assessing the patients for signs of HPV – genital warts, precancerous or cancerous growths and other infections – from three-and-a-half years into the study.

Those assessments were carried out twice a year for the next seven years. But by the end of the study, all participants were still disease-free. Notably, those who received the vaccine earlier had a more robust resilience to the virus, judging by the amount of infection-fighter cells in their blood.

‘Now we need to push for more young people to get vaccinated,’ he says. ‘We are doing miserably in the United States.’

The virus is typically spread through vaginal and anal sex and can develop into cancers in the vagina, penis, throat and anus. Nearly all men and women will be contracted with one form of HPV, there are an estimated 150 types, in their lifetime, according to the CDC.

Annually an average of 38,000 cases of HPV-related cancers are diagnosed in the US. Of those cases, 59 percent are women and 41 percent are men. But men are more likely to develop a type of head or neck cancer, known as oropharyngeal squamous cell carcinoma, than women.

The CDC recommends for all children in the US to receive the vaccine between the ages of nine and 12. Forty percent of girls and 22 percent of boys aged 13 to 17 years old had completed the three-vaccine series by 2014, the organization found.

In contrast, the National Health Service in the UK recommends for only females to receive the vaccination between the ages of 12 and 13. There are no plans to extend the vaccine to males at this time because it is ‘unlikely to be cost-effective’, according to the The Joint Committee on Vaccination and Immunization.

The vaccination was first introduced for females in a three-part series to help prevent against cervical cancer that forms in the cervix. Cervical cancer occurs from genital HPV, which is skin-to-skin contact during sex.

US men are now encouraged to receive the jab after data revealed they too were at risk from developing HPV and cancers associated with the virus.

Research has also shown that men who give or receive anal sex increase their risk of developing HPV.
Condoms are a protective barrier that health experts recommend for men use in order to prevent the spread of the virus.

December, 2017|Oral Cancer News|

Immokalee health clinic earns national award for vaccination rate

Source: www.naplesnews.com
Author: Liz Freeman

The public health department in Immokalee set a goal for getting children vaccinated against cancer and brought home a U.S. Centers for Disease Control and Prevention award for its high success rate.

The Florida Department of Health in Collier County, specifically the Immokalee location, was named the regional winner of the 2017 HPV Vaccine Award because of its 76.2 percent vaccine series completion rate among 13 to 15 year olds.

A point-in-time survey in August found 560 children aged 13 to 15 in Immokalee had been vaccinated against HPV, according to a health department spokeswoman.

In the last four years, the Immokalee clinic took on an ambitious campaign in the farmworker community to boost HPV vaccination rates, starting with ensuring that all staff members who have contact with clients are knowledgeable about the virus and the vaccine. The virus is common and can cause certain cancer of the genitals, head and neck. There are about 31,000 new cases of cancer a year caused by the virus, according to the CDC.

Controversy is attached to the HPV vaccine by some groups who argue that getting kids vaccinated may promote early sexual interaction with others. State governments that have authority over school vaccination requirements have faced debate over requiring it and over the cost

State Surgeon General and DOH Secretary Dr. Celeste Philip said she was proud of the Immokalee clinic and its success rate for the vaccinating young people against the virus.

“Their commitment to preventing cancers caused by HPV infection and ensuring that every child and parent that visits the clinic are educated about the benefits of the HPV vaccine has a positive impact on the health of their county and our state,” she said in a news release.

The CDC award criteria stipulates that candidates must achieve a vaccination series rate of at least 70 percent of the patient population aged 13 to 15, both girls and boys, seen in the last two years.

Stephanie Vick, administrator of the Collier health department, said the Immokalee team identified a public health challenge and set out to achieve results.

“Their efforts reflect their professionalism and dedication to tackling what for some groups can be a taboo subject and placed the focus upon a universally accepted prevention subject,” Vick said.

People get HPV from another person during sexual contact, and both men and women can get it. A person can get it even if the partner has no sign or symptoms. About 79 million Americans are infected with some type of HPV, and 14 million people become newly infected each year. Most infections go away by themselves within two years, but sometimes it can take longer and can cause cancer of the genitals, in the back of the throat and the tongue.

Since 2006, the CDC has recommended the HPV vaccine, initially in a three-dose series over six months, and then it changed its recommendation to two doses for people before the 15th birthday. The second does should be given six to 12 months after the first dose.

November, 2017|Oral Cancer News|

Know what’s worse than the risks of getting the HPV vaccine? Getting an HPV-related cancer. Trust me

Source: www.statnews.com
Author: Michael D. Becker

In an era of $500,000 cancer treatments, you’d expect a vaccine series that costs about $300 and helps prevent several types of cancer to be popular with physicians, insurers, and consumers. It’s not, and, as a result, people are dying. I should know — I’m one of them.

The human papillomavirus (HPV) can cause changes in the body that lead to six cancers: cervical, vaginal, and vulvar cancer in women; penile cancer in men; and anal cancer in both women and men. It can also cause oropharyngeal cancer — cancer in the back of the throat, including the base of the tongue and tonsils — in both sexes. In the U.S., approximately 30,000 new cancers attributable to HPV are diagnosed each year.

In 2006, the first vaccine became available to protect against HPV infection. I was 38 years old at the time, well above the upper age limit of 26 the Centers for Disease Control and Prevention recommends for getting the vaccine. Ideally it should be given before the teen years, but can be given up to age 26.

Uptake of the HPV vaccine in the U.S. is abysmal, with just 49 percent of girls and 37 percent of boys having received the recommended HPV vaccination series.

Individuals who oppose the use of vaccines argue that safety concerns should preclude the use of the HPV vaccine. I disagree. The safety and effectiveness of this vaccine to protect against cancer-causing strains of the HPV virus have been unquestionably proven. Others point to side effects of the HPV vaccine as a reason not to vaccinate young Americans. These may include pain, swelling, redness, itching, bruising, bleeding, or a lump at the injection site as well as headache, fever, nausea, dizziness, tiredness, diarrhea, abdominal pain, and sore throat. Most people who get the vaccine experience no side effects from it other than the pain that accompanies most shots.

Missing from the discussion are the risks of not getting the vaccine. As someone with HPV-related oropharyngeal cancer, I can describe a few of them. And I can say with certainty I would gladly have experienced any of the vaccine-related side effects rather than the dozen or so “side effects” of the cancer and its treatment that I’m living with. I’ve illustrated them on the image below.

Some of these side effects, like hair loss, aren’t hazardous. Others are. I’ve spent time in an intensive care unit for my rapid heart rate, and have had to go to the emergency department several times for my pleural effusion and other issues. All of these pale beside the biggest “side effect” — a terminal disease that will eventually take my life.

I urge all parents to talk to your child’s doctor about the HPV vaccine. I wish my parents had that opportunity when I was young, as it could have prevented the cancer that’s killing me.

November, 2017|Oral Cancer News|

HPV-related oral cancers have risen significantly in Canada

Source: www.ctvnews.ca
Author: Sheryl Ubelacker, The Canadian Press

The proportion of oral cancers caused by the human papillomavirus has risen significantly in Canada, say researchers, who suggest the infection is now behind an estimated three-quarters of all such malignancies. In a cross-Canada study, published Monday in the Canadian Medical Association Journal, the researchers found the incidence of HPV-related oropharyngeal cancers increased by about 50 per cent between 2000 and 2012.

“It’s a snapshot of looking at the disease burden and the time trend to see how the speed of the increase of this disease (is changing),” said co-author Sophie Huang, a research radiation therapist at Princess Margaret Cancer Centre in Toronto.

Researchers looked at data from specialized cancer centres in British Columbia, Alberta, Ontario and Nova Scotia to determine rates of HPV-related tumours among 3,643 patients aged 18 years or older who had been diagnosed with squamous cell oropharyngeal cancer between 2000 and 2012.

HPV is the most common sexually transmitted infection worldwide. Most people never develop symptoms and the infection resolves on its own within about two years.

“In 2000, the proportion of throat cancer caused by HPV was estimated at 47 per cent,” said Huang. “But in 2012, the proportion became 74 per cent … about a 50 per cent increase.”

Statistics from a Canadian Cancer Society report last fall showed 1,335 Canadians were diagnosed in 2012 with HPV-related oropharyngeal cancer and 372 died from the disease.

HPV is the most common sexually transmitted infection worldwide. Most people never develop symptoms and the infection resolves on its own within about two years. But in some people, the infection can persist, leading to cervical cancer in women, penile cancer in men and oropharyngeal cancer in both sexes.

Most cases of HPV-related oral cancer are linked to oral sex, said Huang, noting that about 85 per cent of the cases in the CMAJ study were men.

HPV-related tumours respond better to treatment and have a higher survival rate than those linked to tobacco and alcohol use, the other major cause of oral cancer, she said, adding that early identification of a tumour’s cause is important to ensure appropriate and effective treatment.

While some centres in Canada routinely test oral tumours to determine their HPV status, such testing is not consistent across the country, the researchers say.

In the past, physicians generally tended to reserve tumour testing for cases most likely to be caused by HPV – among them younger males with no history of smoking and with light alcohol consumption – to prevent an unnecessary burden on pathology labs.

“Only as accumulating data have supported the clinical importance of HPV testing has routine testing been implemented in most (though not all) Canadian centres,” the researchers write.

The study showed that the proportion of new HPV-related oral cancers rose as those caused by non-HPV-related tumours fell between 2000 and 2012 – likely the result of steadily declining smoking rates.

Huang said males tend to have a weaker immune response to HPV than do females, which may in part explain the higher incidence of oral cancers linked to the virus in men.

HPV vaccines given to young people before they become sexually active can prevent infection – and the researchers say both boys and girls should be inoculated.

Currently, six provinces provide HPV immunization to Grade 6 boys as well as girls, with the other four provinces set to add males to vaccination programs this fall, said Huang.

“So vaccinating boys is very important because, if you look at Canadian Cancer Society statistics (for 2012), HPV- related oropharyngeal cancer in total numbers has already surpassed cervical cancers,” she said.
“The increase of HPV-related cancer is real, and it’s striking that there’s no sign of a slowdown.”

August, 2017|Oral Cancer News|